While overall industry performance is trending positive, quality failures continue to negatively impact patients and the bio/pharma industry.
While patients generally trust that the drugs they take are safe, product recalls, drug shortages, reports of potential contaminants, and publicized regulatory enforcement actions can shake public confidence in the drug supply. While FDA looks to encourage voluntary compliance over the “stick” approach of tighter enforcement, biopharma companies are encouraged to build a quality culture throughout the organization, starting with top executives at the company.
Read this article in BioPharm International’s September 2019 Regulatory Sourcebook.
BioPharm International
eBook: Regulatory Sourcebook, September 2019
September 2019
Pages: 4–6
When referring to this article, please cite it as R. Peters, “Quality Culture Drives Patient Confidence in Drug Products," BioPharm International Regulatory Sourcebook eBook (September 2019).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.